论文部分内容阅读
目的研究干扰素调节因子3(IRF3)基因多态性在慢性淋巴细胞白血病(CLL)患者中的表达,探讨其基因型在CLL预后中的意义。方法采用变性高效液相色谱法(DHPLC)对患者样本进行基因分型,对IRF3基因的3个位点rs7251、rs1140375和rs2304206进行单体基因型分析,同期检测常规预后相关指标。结果 CLL患者经过治疗后,rs7251各基因型中无事件生存率(EFS)分别为:32.0%(杂合型CG和突变型GG)和72.7%(野生型CC),CC基因型患者EFS明显高于携带CG+GG基因型患者。rs2304206各基因型中EFS分别为28.2%(杂合型CT和突变型TT)和62.5%(野生型CC),CC基因型患者EFS高于携带CT+TT基因型患者;rs7251位点的杂合型CG和突变型GG基因型、rs2304206位点的杂合型CT和突变型TT基因型的ZAP-70、CD38表达率明显高于表达rs7251位点的野生型CC和表达rs2304206位点的野生型CC基因型,上述差异均有统计学意义(P<0.05)。结论 IRF-3基因多态性与汉族人群CLL预后相关,IRF-3基因多态性可能与ZAP-70、CD38两项临床预后指标具有相关性,IRF-3基因多态性检测可作为一个新的相对独立的CLL患者生存预后指标。
Objective To investigate the expression of interferon regulatory factor 3 (IRF3) gene polymorphism in patients with chronic lymphocytic leukemia (CLL) and to explore the significance of its genotype in the prognosis of CLL. Methods The genotypes of patients were genotyped by denaturing high performance liquid chromatography (DHPLC). The haplotypes of rs7251, rs1140375 and rs2304206 of IRF3 gene were analyzed at 3 sites, and the indexes of routine prognosis were detected at the same period. Results After treatment, the event-free survival (EFS) of rs7251 genotypes in CLL patients were 32.0% (heterozygous CG and mutant GG) and 72.7% (wild type CC), respectively. The EFS of CC genotype patients were significantly higher In patients with CG + GG genotypes. The EFS of rs2304206 genotypes were 28.2% (heterozygous CT and mutant TT) and 62.5% (wild type CC) respectively. The EFS of CC genotype patients was higher than that of patients with CT + TT genotypes. The rs7251 heterozygosity CG and mutant GG genotypes, the ZAP-70 and CD38 expression rates of rs2304206 heterozygous CT and mutant TT genotypes were significantly higher than those of wild-type CCs expressing rs7251 and wild type rs2304206 CC genotype, the above differences were statistically significant (P <0.05). Conclusion The polymorphism of IRF-3 gene is associated with the prognosis of CLL in Han population. The polymorphism of IRF-3 gene may be related to the clinical prognostic factors of ZAP-70 and CD38, and the detection of IRF-3 gene polymorphism may be used as a new Relative survival prognostic indicators of CLL patients.